|Day Low/High||0.94 / 0.99|
|52 Wk Low/High||0.84 / 4.32|
Ampio Pharma (AMPE) stock is sharply lower this afternoon following a phase 3 trial for its osteoarthritis pain treatment.
Ampio to request approval from the FDA for the treatment of pain due to severe osteoarthritis of the knee.
Aytu and Ampio to Host Joint Webcast and Conference Call Today at 4:15 PM EST
Ampio Pharmaceuticals (AMPE) shares are up over 10% after the company received Special Protocol Assessment from the FDA.
The Rosen Law Firm reminds purchasers of Ampio Pharmaceuticals, Inc.